Abstract 120P
Background
Cetuximab (Cet) plus chemotherapy (CT) has been approved as preferred first-line (1L) treatment for left-sided (LS) metastatic colorectal cancer (mCRC) with wild-type (wt) RAS/BRAF gene. However, it remains uncertain whether Cet is beneficial as maintenance therapy after 1L treatment. This study aimed to investigate the clinical outcomes for maintenance therapy in pts with LS RAS/BRAF wt mCRC who responded to 1L Cet plus CT.
Methods
We performed a retrospective review of pts with LS RAS/BRAF wt mCRC who had disease controlled (CR, PR or SD) after 6 cycles of Cet based induction therapy from JAN 2018 to JUN 2022 at HuNan Cancer Hospital. The 1L regimen consists of Cet plus mFOLFOX6 or FOLFIRI, based on pts selection, followed by maintenance therapy with Cetuximab with or without chemotherapy (cohort A) or chemotherapy alone (cohort B). Death data were obtained from the government's death registry. Kaplan-Meier methods were employed to describe overall survival (OS) and progression-free survival (PFS).
Results
A total of 125 pts were included in this study, with 72 (57.6%) in cohort A and 53 (42.4%) in cohort B. The median age was 58 years (range: 23-76), and 86 (68.8%) were male. The most common site of metastasis was the liver (90 patients, 72.0%). During a median follow-up of 32.6 m, the median OS from the start of 1L therapy was significantly longer in cohort A (46.4 m, 95% CI 40.1-NA) than in cohort B (31.1 m, 95% CI 27.6-38.0; p < 0.0001). Similarly, cohort A (14.2 m, 95% CI 12.4-17.0) had a significantly longer median PFS than cohort B (11.0 m, 95% CI 9.6-11.7; p=0.021). The Cox proportional hazards model, after adjusting for age, sex, primary tumor location, metastatic site, and whether the primary tumor and metastases were resected or not, showed that compared with cohort B, cohort A was associated with a statistically significant longer OS (HR 0.43, 95% CI 0.25-0.73) and a longer PFS, although the difference was not statistically significant (HR 0.70, 95% CI 0.44-1.12).
Conclusions
Maintenance therapy with Cet can significantly improve OS in pts with LS RAS/BRAF wt mCRC and lead to a clinically meaningful improvement in PFS, although the statistical difference was not reached.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract